Living with Thyroid cancer, nonmedullary, 2
An inherited form of thyroid cancer that starts in the thyroid's follicular cells and runs in families.
Understanding Thyroid cancer, nonmedullary, 2
Nonmedullary thyroid cancer is more than 95% of all thyroid cancers and has four groups: papillary, follicular, Hurthle cell, and anaplastic. About 5% is hereditary. Papillary is the most common subtype in families, and follicular tends to spread through the bloodstream to the lungs and bones.
Signs & symptoms
GARD doesn't list specific symptoms for this condition yet.
Not everyone has every symptom. GARD's list comes from the Human Phenotype Ontology.
Diagnosis
- 1Talk with your doctor
Share the symptoms you've noticed, when they started and your family health history. Notes and photos can help.
- 2See a specialist
Your doctor may refer you to a specialist who knows rare conditions.
- 3Ask which tests can help
Your care team will decide which exams and tests can confirm the diagnosis.
Care & treatment
- Care team
- A doctor familiar with rare conditions, plus specialists as needed
- Expert care
- Ask about multidisciplinary care centers for rare conditions
- Treatment
- GARD doesn't list specific treatments for this condition. Your care team will tailor care to your symptoms.
- Research
- Clinical trials and observational studies may be options. See the research section below.
General information, not medical advice. Your care team makes the decisions.
Everyday life
Living with a rare condition is easier with support.
- Connect with ThyCa: Thyroid Cancer Survivors' Association, Inc.
- Keep notes on symptoms, changes and questions for appointments
- Ask about patient registries that help research
- Look into financial aid and travel resources for care visits
Quick facts
NMTC2 is linked to a changed copy of the SRGAP1 gene. It is autosomal dominant, which means one changed copy of the gene can be enough to raise the risk.
Also known as: nmtc2; thyroid cancer, nonmedullary, 2, autosomal dominant, somatic mutation; thyroid cancer, nonmedullary, 2, susceptibility to; thyroid cancer, nonmedullary, type 2; thyroid carcinoma, follicular; thyroid carcinoma, follicular, autosomal dominant, somatic mutation
Patient organizations
- ThyCa: Thyroid Cancer Survivors' Association, Inc.Thyroid cancer, nonmedullary, 2 · United States
You are more than your diagnosis
Perspectives from people navigating life with Thyroid cancer, nonmedullary, 2.
Explore research for Thyroid cancer, nonmedullary, 2
Explore actively recruiting Thyroid cancer, nonmedullary, 2 studies with HealthSpark.
Find actively recruiting studies for Thyroid cancer, nonmedullary, 2 with HealthSpark. Share your city to explore research near you.
- Recruiting studies from ClinicalTrials.gov
- Share your city to look for research near you
- Eligibility is confirmed by the study team
Powered by HealthSpark, our AI chat helper
I can help you find recruiting Thyroid cancer, nonmedullary, 2 studies. Enter a ZIP code, address or city below and I'll look within 50 miles.
Powered by HealthSpark, our AI chat helper · Study information from ClinicalTrials.gov · Eligibility is confirmed by the study team.
Get Signals for Thyroid cancer, nonmedullary, 2
Stay in the loop with community stories and updates from medical researchers.
Create a living journal that talks back
HealthStory evolves private journaling with a living AI journal that talks back and asks thoughtful questions, helping you capture your Thyroid cancer, nonmedullary, 2 experiences more deeply and prepare for better conversations with your doctors and care team.
Your journal is private. Sharing your story publicly is a separate choice, made with Share your story above.